|
|
 |
|
Viewing report
|
|
|
|
Asthma and COPD Drug Discoveries: what the future holds
Espicom Business Intelligence Ltd, Aug 2006, Pages: 96
A rapidly expanding sector
An estimated 300 million people around the world have asthma and the European Federation of Allergy and Airway Diseases Patients Association have indicated that this could increase to 400-450 million by 2025. Around 30 million people in Europe have asthma, six million of whom have severe symptoms and around 1.5 million live in fear of dying from an attack.
COPD is one of the top five causes of disability and death in industrial societies. According to the WHO, COPD is the fourth leading cause of death worldwide, based on 2004 data. In the US, COPD is projected to be the third leading cause of death by 2020.
Results of the National Health Interview Survey in the US indicate that 12.1 million adults over the age of 25 reported being diagnosed with COPD in 2001. Of these, 9.2 million reported being diagnosed with chronic bronchitis, 2 million with emphysema and 0.9 million with both conditions. According to the National Heart, Blood and Lung Institute, this compares with around 24 million adults in the US who have evidence of impaired lung function, which suggests COPD is under-diagnosed.
According to the European Respiratory Society, the total cost of asthma in Europe is €17.7 billion per year (White Book, 2003). In the UK, around 5.2 million people are currently receiving treatment for asthma. Of these, 1.1 million are children, equivalent to one in ten. According to Asthma UK, asthma costs the NHS an average of £889 million per year.
Questions, Questions
What global revenue is Boehringer Ingelheim’s novel COPD treatment Spiriva forecast to achieve in 2011?
What issue may effect the growth of Novartis/Genetech’s Xolair in Europe?
What future revenues could be expected by AstraZeneca following the recent approval of Symbicort in the US?
To what degree will generic competition effect future revenues of GSK’s market leading Seretide/Advair?
There are 29 compounds for Asthma and COPD in Phase I/II - what are they and who’s developing them?
Current products evaluated and forecast to 2011 in the report
Xopenex
levalbuterol, Sepracor
Flixotide/Flovent
fluticasone propionate, GSK
Pulmicort
budesonide, AstraZeneca
Asmanex
mometasone furoate, GSK
Alvesco
ciclesonide+formoterol, Altana
Spiriva
tiotropium, Boehringer Ingelheim
Seretide/Advair
fluticasone+salmeterol, GSK
Symbicort
budesonide+formoterol, AstraZeneca
Singulair
montelukast, Merck
Xolair
omalizumab, Genentech/Novartis
Future products evaluated and forecast in the report
Ariflo
Clomilast, GSK
Daxas
roflumilast, Altana
Arformoterol
Sepracor
Indacaterol
Novartis
GSK 159797
GSK
NVA237
Novartis
Customers who bought this item also bought
Product Profiles: Asthma/COPD - Novel Combinations Edge Closer to Market
Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Chronic Obstructive Pulmonary Disease - Global Strategic Business Report
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
IMS Therapy Report: Asthma & COPD
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Market and Product Forecasts: COPD - Growth expected despite untapped market potential
Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
Pricing and Reimbursement Issues for Immune Disease Therapies
|
|
|
|
